Limits...
Serratiopeptidase Niosomal Gel with Potential in Topical Delivery.

Shinde UA, Kanojiya SS - J Pharm (Cairo) (2014)

Bottom Line: The entrapment efficiency was found to be influenced by the molar ratio of Span 40 : cholesterol and concentration of SRP in noisome.Furthermore ex vivo skin permeation revealed that there was fourfold increase in a steady state flux when SRP was formulated in niosomes and a significant increase in the permeation of SRP, from SRP niosomal gel containing permeation enhancer.In vivo efficacy studies indicated that SRP niosomal gel had a comparable topical anti-inflammatory activity to that of dicolfenac gel.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai 400098, India.

ABSTRACT
The objective of present study was to develop nonionic surfactant vesicles of proteolytic enzyme serratiopeptidase (SRP) by adapting reverse phase evaporation (REV) technique and to evaluate the viability of SRP niosomal gel in treating the topical inflammation. The feasibility of SRP niosomes by REV method using Span 40 and cholesterol has been successfully demonstrated in this investigation. The entrapment efficiency was found to be influenced by the molar ratio of Span 40 : cholesterol and concentration of SRP in noisome. The developed niosomes were characterized for morphology, particle size, and in vitro release. Niosomal gel was prepared by dispersing xanthan gum into optimized batch of SRP niosomes. Ex vivo permeation and in vivo anti-inflammatory efficacy of gel formulation were evaluated topically. SRP niosomes obtained were round in nanosize range. At Span 40 : cholesterol molar ratio 1 : 1 entrapment efficiency was maximum, that is, 54.82% ± 2.08, and showed consistent release pattern. Furthermore ex vivo skin permeation revealed that there was fourfold increase in a steady state flux when SRP was formulated in niosomes and a significant increase in the permeation of SRP, from SRP niosomal gel containing permeation enhancer. In vivo efficacy studies indicated that SRP niosomal gel had a comparable topical anti-inflammatory activity to that of dicolfenac gel.

No MeSH data available.


Related in: MedlinePlus

In vitro release of SRP through cellulose acetate membrane.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4590824&req=5

fig2: In vitro release of SRP through cellulose acetate membrane.

Mentions: In vitro release studies were carried out in triplicate using cellulose acetate membrane (0.45 μ) to assess the release of SRP from SRP niosomal dispersion. Percent cumulative release of SRP from SRP niosomal dispersion is indicated in Figure 2. The percent cumulative release from SRP niosomal dispersion was found to be slow and sustained release as compared to percent cumulative release from aqueous solution of SRP. At the end of sixth hour the drug release from noisome was 22.01 ± 0.79%, whereas from aqueous solution of SRP it was 32.47 ± 0.65%. Hence, sustained release pattern was observed. It is clear that the release is slower from multilamellar niosomes. This may be attributed to the fact that multilamellar vesicles consist of several concentric spheres of surfactant which are rigidized by cholesterol. Therefore, the diffusion of SRP entrapped in the multilamellar vesicles would be expected to occur over a prolonged period of time. Cholesterol is known to abolish the gel to sol phase transition of niosome systems; hence resulting niosomes are less leaky thus reducing SRP release from niosomes.


Serratiopeptidase Niosomal Gel with Potential in Topical Delivery.

Shinde UA, Kanojiya SS - J Pharm (Cairo) (2014)

In vitro release of SRP through cellulose acetate membrane.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4590824&req=5

fig2: In vitro release of SRP through cellulose acetate membrane.
Mentions: In vitro release studies were carried out in triplicate using cellulose acetate membrane (0.45 μ) to assess the release of SRP from SRP niosomal dispersion. Percent cumulative release of SRP from SRP niosomal dispersion is indicated in Figure 2. The percent cumulative release from SRP niosomal dispersion was found to be slow and sustained release as compared to percent cumulative release from aqueous solution of SRP. At the end of sixth hour the drug release from noisome was 22.01 ± 0.79%, whereas from aqueous solution of SRP it was 32.47 ± 0.65%. Hence, sustained release pattern was observed. It is clear that the release is slower from multilamellar niosomes. This may be attributed to the fact that multilamellar vesicles consist of several concentric spheres of surfactant which are rigidized by cholesterol. Therefore, the diffusion of SRP entrapped in the multilamellar vesicles would be expected to occur over a prolonged period of time. Cholesterol is known to abolish the gel to sol phase transition of niosome systems; hence resulting niosomes are less leaky thus reducing SRP release from niosomes.

Bottom Line: The entrapment efficiency was found to be influenced by the molar ratio of Span 40 : cholesterol and concentration of SRP in noisome.Furthermore ex vivo skin permeation revealed that there was fourfold increase in a steady state flux when SRP was formulated in niosomes and a significant increase in the permeation of SRP, from SRP niosomal gel containing permeation enhancer.In vivo efficacy studies indicated that SRP niosomal gel had a comparable topical anti-inflammatory activity to that of dicolfenac gel.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai 400098, India.

ABSTRACT
The objective of present study was to develop nonionic surfactant vesicles of proteolytic enzyme serratiopeptidase (SRP) by adapting reverse phase evaporation (REV) technique and to evaluate the viability of SRP niosomal gel in treating the topical inflammation. The feasibility of SRP niosomes by REV method using Span 40 and cholesterol has been successfully demonstrated in this investigation. The entrapment efficiency was found to be influenced by the molar ratio of Span 40 : cholesterol and concentration of SRP in noisome. The developed niosomes were characterized for morphology, particle size, and in vitro release. Niosomal gel was prepared by dispersing xanthan gum into optimized batch of SRP niosomes. Ex vivo permeation and in vivo anti-inflammatory efficacy of gel formulation were evaluated topically. SRP niosomes obtained were round in nanosize range. At Span 40 : cholesterol molar ratio 1 : 1 entrapment efficiency was maximum, that is, 54.82% ± 2.08, and showed consistent release pattern. Furthermore ex vivo skin permeation revealed that there was fourfold increase in a steady state flux when SRP was formulated in niosomes and a significant increase in the permeation of SRP, from SRP niosomal gel containing permeation enhancer. In vivo efficacy studies indicated that SRP niosomal gel had a comparable topical anti-inflammatory activity to that of dicolfenac gel.

No MeSH data available.


Related in: MedlinePlus